By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Drug Companies Need Evidence Generation Strategies
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Drug Companies Need Evidence Generation Strategies
Policy & Law

Drug Companies Need Evidence Generation Strategies

Aises Jammy
Aises Jammy
Share
5 Min Read
gather evidence on the effectiveness of new drugs
Shutterstock Photo License - Dmitry Kalinovsky
SHARE

The pharmaceutical industry has undergone some tremendous changes in recent years. Despite changes brought on by the Patient Protection and Affordable Care Act and other trends, it is still one of the largest industries in the United States and the rest of the world. The global market for pharmaceuticals is currently worth over $405 billion.

Contents
  • Drug Companies Need to Generate Evidence Proving the Quality of their Products
  • Evidence generation strategy – what is it
  • Why pharmaceutical companies need an evidence-gathering strategy
  • Key Elements of Strategic Research Planning
    • Evidence strategy development by consulting firms

Although there are a lot of opportunities as a drug manufacturer, there are also some challenges. Drug companies are under a lot of pressure to create the highest quality pharmaceuticals to meet the needs of their customers.

In order to achieve this goal, they have to get the evidence needed to prove the safety and efficacy of their products. Keep reading to learn how they can do this.

Drug Companies Need to Generate Evidence Proving the Quality of their Products

Every year the competition in the drug market is getting more challenging. This is one of the biggest trends shaping the industry. Each new drug they develop requires a comparative evaluation and proof of its effectiveness and economic value.

More Read

Boomers Reluctant to Curtail Lifestyle in Retirement
Is Medical Accountability a Thing of the Past?
How Much do Financial Incentives Matter to Physicians?
Dangers of Pneumonia for the Elderly
Understanding the Legal Aspects of Wrongful Death in Healthcare

At the same time, the evidence requirements are getting stricter. The FDA and other regulators require pharmaceutical companies to demonstrate the safety of their products, especially when there is so much controversy over things like the COVID-19 vaccines. For this reason, obtaining comprehensive evidence of the value of manufactured products has become critical in the pharmaceutical industry over the past few years. In addition, a strategic research approach contributes to an evidence base that can be shared with all stakeholders on time.

Evidence generation strategy – what is it

Developing new pharmaceuticals is a process of evidence generation that the following qualities can characterize:

  • a focus on the outcome defined by the producing company;
  • full use of available data;
  • the detailed design of all research work;
  • the systematicity and standardization of research.

The result of such work is the creation of a single database of evidence, which demonstrates the new pharmaceutical’s value to payers and decision-makers.

There is growing pressure to improve the quality of evidence as the drug industry changes. The necessary steps in developing an evidence strategy are:

  • collecting and analyzing existing data, market research, and identifying competitive issues to identify gaps in the existing evidence base;
  • establishing the key value of a new drug or technology;
  • identifying and prioritizing the evidence supporting the key value of the novelty; 
  • identifying the resources required to collect the data, establishing a timetable for the work;
  • creating a publication plan and a strategy for communicating the generated evidence base to stakeholders.

In other words, developing an evidence strategy comes down to comprehensive planning of the research work. The main objective of such planning is to structure and align the data collection process with specific strategic goals.

Why pharmaceutical companies need an evidence-gathering strategy

Such companies have a complex organizational structure due to pharmaceutical product development, manufacturing, and sales processes. This, in turn, makes data collection for the evidence base more difficult because the more complex an organization is, the more difficult it is to establish communication between its departments and employees.

Developing an evidence base strategy allows research to be organized more quickly. As a consequence, the process of generating, verifying, and communicating evidence to clients and decision-makers is also much faster. This, in turn, makes the decision-making processes for market admissions and monetary compensation happen as quickly as possible, which gives the company a competitive advantage.

Key Elements of Strategic Research Planning

Effective strategic planning for obtaining evidence on new drugs includes:

  • top-level scientific expertise (both therapeutic and methodological);
  • A consistent approach;
  • Recommendations for developing an evidence base that is solution-oriented and communication-oriented;
  • emphasis on obtaining the evidence needed for a particular audience.

Drug company executives appreciate the need to do these things as rigorously as possible.

Evidence strategy development by consulting firms

Today, many consulting companies like digitalho offer evidence strategy development services. For this purpose, they use modern digital solutions that allow them to work with large amounts of information and new data types. The result of a competent development of a strategic approach to evidence generation is a comprehensive research strategy that will work for more than one year at all stages of product creation.

TAGGED:drug industrypharmaceutical companiespharmaceutical industry
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

What Are the Steps to Obtain Health Equity Accreditation?
What Are the Steps to Obtain Health Equity Accreditation?
Health
December 18, 2025
a cosmetologist doing beauty treatment to a woman
Compliance Regulations for Aesthetic Clinics in the EU
Health Women Health
December 18, 2025
sunlit portrait with delicate lace shadows
Dr. Michael Piepkorn: Understanding The Genetic Links Behind Familial Skin Cancer
Skin
December 17, 2025
post-surgical recovery
Your Guide To Key Milestones In At Home Post-Surgical Recovery
Health Infographics
December 14, 2025

You Might also Like

paramedics in surgical gloves and masks
Health care

How Health Choices and Legal Actions Intersect After an Injury

July 16, 2025
healthcare economics uwe reinhardt
Policy & Law

#ObamaCare and You: Uwe Reinhardt Discusses HealthCare Economics

October 17, 2013
healthcare cybersecurity
HealthPolicy & LawTechnology

4 Helpful Tips on How to Protect Your Medical Practice Against Cyber Attacks

October 22, 2021

Long Term Care Insurance: Narrow Framing Is Not the Problem

June 18, 2015
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?